BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down – Here’s Why

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares gapped down prior to trading on Monday . The stock had previously closed at $8.43, but opened at $7.77. BioCryst Pharmaceuticals shares last traded at $7.15, with a volume of 1,709,944 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BCRX shares. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. JMP Securities increased their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 6th. Barclays boosted their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.67.

BioCryst Pharmaceuticals Price Performance

The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -11.57 and a beta of 1.89. The firm has a 50-day moving average price of $7.82 and a two-hundred day moving average price of $6.97.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same period last year, the company earned ($0.19) EPS. The company’s revenue was up 35.1% compared to the same quarter last year. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.37 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Large investors have recently modified their holdings of the business. CWM LLC grew its stake in BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC grew its stake in shares of BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,599 shares in the last quarter. Seven Eight Capital LP bought a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at $57,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares during the last quarter. Finally, Natixis raised its position in BioCryst Pharmaceuticals by 400.6% during the first quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 9,350 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.